1. Introduction {#sec1-jcm-07-00338}
===============

Patients with atrial fibrillation (AF) are at substantial risk of ischemic stroke and systemic embolism. Oral anticoagulation therapy has been shown to be effective in preventing thromboembolic complications \[[@B1-jcm-07-00338],[@B2-jcm-07-00338],[@B3-jcm-07-00338],[@B4-jcm-07-00338],[@B5-jcm-07-00338],[@B6-jcm-07-00338]\]. However, such therapy has also been shown to increase the risk of major bleeding \[[@B3-jcm-07-00338],[@B7-jcm-07-00338],[@B8-jcm-07-00338],[@B9-jcm-07-00338]\]. Therefore, the benefits of treatment should be weighed against the risks.

To estimate the incidence of systemic embolism and major bleeding in patients with AF, an evidence-based scoring system is needed. The CHADS~2~ score is one of the most studied models \[[@B10-jcm-07-00338]\], and it has been used to estimate the risk of ischemic stroke and systemic embolism. The subsequently released CHA~2~DS~2~-VASc score contains more parameters \[[@B11-jcm-07-00338]\], and its use is recommended in current guidelines \[[@B12-jcm-07-00338],[@B13-jcm-07-00338]\].

In general, non-valvular AF patients with higher CHA~2~DS~2~-VASc scores are considered to be more susceptible to thromboembolic events. Warfarin and non-vitamin K oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban have been shown to be effective in reducing the risk of ischemic stroke and systemic embolism \[[@B2-jcm-07-00338],[@B3-jcm-07-00338],[@B4-jcm-07-00338]\]. In addition, current guidelines recommend that the risk of bleeding is assessed before initiating oral anticoagulant (OAC) therapy \[[@B12-jcm-07-00338],[@B13-jcm-07-00338]\]. Several scoring systems such as the HEMORR~2~HAGES, HAS-BLED, ATRIA, ORBIT, and ABC systems have been used to predict the risk of bleeding for patients under OAC treatment \[[@B14-jcm-07-00338],[@B15-jcm-07-00338],[@B16-jcm-07-00338],[@B17-jcm-07-00338],[@B18-jcm-07-00338]\].

Although it has been reported that higher CHA~2~DS~2~-VASc scores are also associated with an increased incidence of major bleeding in patients receiving warfarin or rivaroxaban \[[@B19-jcm-07-00338],[@B20-jcm-07-00338]\], it is not known whether this phenomenon would be observed in patients taking other NOACs such as dabigatran and apixaban. In this study, we investigated this issue using a nationwide medical insurance claiming database in Taiwan.

2. Materials and Methods {#sec2-jcm-07-00338}
========================

2.1. Patients {#sec2dot1-jcm-07-00338}
-------------

We used the National Health Insurance Research Database (NHIRD) of Taiwan to analyze patients between 2010 and 2016 with a diagnosis of AF. The International Statistical Classification of Disease and Related Health Problems, Ninth Revision, Clinical Modification (ICD-9-CM) code 427.31 and International Statistical Classification of Disease and Related Health Problems, Tenth Revision, Clinical Modification (ICD-10-CM) code 148 were used to select AF patients. A total of 279,776 cases were identified. Those not prescribed with warfarin or any of the three NOACs (dabigatran, rivaroxaban, and apixaban), and those who had ever used more than one of these NOACs were excluded. The other major exclusion criteria were the occurrence of pulmonary embolism, valvular surgery, or hemodialysis within 6 months before the index date, defined as the date of the first warfarin or NOAC prescription. The flow chart of subject enrollment is shown in [Figure 1](#jcm-07-00338-f001){ref-type="fig"}. We divided the target patients into four groups: apixaban (5843 patients, 8.00%), rivaroxaban (27,777 patients, 38.01%), dabigatran (20,079 patients, 27.48%), and warfarin (19,375 patients, 26.51%). All comorbidities in [Table 1](#jcm-07-00338-t001){ref-type="table"} were defined as events leading to at least two outpatient visits and/or hospitalization at least once. The CHA~2~DS~2~-VASc score contains seven categories: congestive heart failure, hypertension, age, diabetes mellitus, stroke, vascular disease, and sex. ICD-9-CM and ICD-10-CM codes were used to identify these diseases. Because some drugs, such as anti-platelet agents and Non-steroidal anti-inflammatory drugs (NSAIDs), reduce the occurrence of bleeding, they were considered as well.

2.2. Outcomes {#sec2dot2-jcm-07-00338}
-------------

The study outcomes were major bleeding, ischemic stroke, and systemic embolism. Major bleeding was defined as intracranial bleeding, gastrointestinal bleeding, and any bleeding events in patients who needed hospitalization. Only outcomes which occurred after the index date were counted.

2.3. Statistical Methods {#sec2dot3-jcm-07-00338}
------------------------

Incidence rates were computed using the total number of study outcomes during the follow-up period divided by person-years at risk. Cumulative incidence rates were also computed by the total number of study outcomes during the follow-up period divided by persons involved at the index date. ANOVA or the chi-squared test was used to compare data among the four groups, where appropriate. Statistical significance was defined as a *p* value \< 0.05. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-jcm-07-00338}
==========

The baseline characteristics of the studied patients are listed in [Table 1](#jcm-07-00338-t001){ref-type="table"}. Major bleeding events were recorded in 69, 739, 649, and 911 patients in the apixaban, rivaroxaban, dabigatran, and warfarin groups, respectively ([Figure 2](#jcm-07-00338-f002){ref-type="fig"}). The cumulative incidence rates of major bleeding in 2.5 years were 1.18%, 2.66%, 3.23%, and 4.70%, respectively. Except for the patients with a CHA~2~DS~2~-VASc score of one in the warfarin group, the events occurred more frequently in the patients with higher scores, especially scores of five or higher (2.23%, 3.06%, 2.73%, and 5.63%, respectively).

Ischemic stroke or systemic embolism was observed in 101, 1008, 876, and 973 patients in the apixaban, rivaroxaban, dabigatran, and warfarin groups, respectively ([Figure 3](#jcm-07-00338-f003){ref-type="fig"}), corresponding to cumulative incidence rates of 1.73%, 3.62%, 4.36%, and 5.02%. As the CHA~2~DS~2~-VASc score increased, more events were noted in all but the apixaban group (with a score of three). The highest event rate was seen in the patients with a CHA~2~DS~2~-VASc score of five or more (3.78%, 5.23%, 4.66%, and 7.06% in the apixaban, rivaroxaban, dabigatran, and warfarin groups, respectively). In all four groups, where there was a CHA~2~DS~2~-VASc score of five or more, the risk of stroke or systemic embolism was higher than the risk of major bleeding ([Figure 4](#jcm-07-00338-f004){ref-type="fig"}).

4. Discussion {#sec4-jcm-07-00338}
=============

Warfarin has been considered a standard treatment in the prevention of atrial fibrillation-related thromboembolism. Previous studies proved that the patients receiving NOACs enjoyed similar preventive effects and a lower risk of major bleeding \[[@B12-jcm-07-00338],[@B13-jcm-07-00338],[@B21-jcm-07-00338]\]. Efficacy and safety have also been highlighted in electrical cardioversion and transcatheter radiofrequency cardiac ablation \[[@B22-jcm-07-00338],[@B23-jcm-07-00338],[@B24-jcm-07-00338]\]. The evidence supported that NOACs would be some of the first drug choices in the treatment of non-valvular atrial fibrillation. To further stratify the benefit and the risk of the patients under the treatment of different NOACs, we conducted this large-population study. It revealed a correlation between CHA~2~DS~2~-VASc score and major bleeding in non-valvular atrial fibrillation (NVAF) patients. We found that the patients with higher CHA~2~DS~2~-VASc scores were more susceptible to both major bleeding and systemic thromboembolism.

Current guidelines suggest the use of CHA~2~DS~2~-VASc scores to estimate the risk of ischemic stroke for non-valvular AF patient and initiate oral anticoagulant therapy accordingly (a score of two for male or more for female patients). To reduce the incidence of bleeding, the guidelines also recommend using scoring systems such as the HAS-BLED, ORBIT, or ABC scores, to identify patients at high risk of bleeding. However, the benefits of thromboembolic prevention should be weighed against the risk of major bleeding \[[@B12-jcm-07-00338],[@B13-jcm-07-00338]\].

An association between CHA~2~DS~2~-VASc scores and the incidence of major bleeding has been reported in several previous studies \[[@B19-jcm-07-00338],[@B20-jcm-07-00338]\], in which a higher risk of bleeding was noted in patients with higher CHA~2~DS~2~-VASc scores who were also receiving warfarin or rivaroxaban. We also found a similar association in the patients taking dabigatran or apixaban. This finding should serve to remind clinicians that AF patients at high risk of thromboembolic events are also at a considerably higher risk of bleeding. This may be because these two different types of complications share similar risk factors.

There are several possible explanations why the CHA~2~DS~2~-VASc score may predict major bleeding. For example, the CHA~2~DS~2~-VASc and HAS-BLED scores share similar risk factors, including hypertension, old age, and history of prior stroke \[[@B11-jcm-07-00338],[@B15-jcm-07-00338]\]. The CHA~2~DS~2~-VASc score includes diabetes mellitus, which has a high incidence in patients with chronic kidney disease, which in turn is a component of the HAS-BLED score \[[@B25-jcm-07-00338]\]. The associations among coronary artery disease, peripheral artery disease, heart failure, and major bleeding may be more complicated. Patients with coronary or peripheral artery disease receive long-term anti-platelet therapy, which can increase the risk of bleeding \[[@B26-jcm-07-00338],[@B27-jcm-07-00338],[@B28-jcm-07-00338]\]. The prevalence of coronary or peripheral artery diseases is higher in patients with chronic kidney disease than in the general population \[[@B29-jcm-07-00338]\]. Heart failure patients are also susceptible to ischemic heart disease, peripheral artery disease, and chronic kidney disease \[[@B30-jcm-07-00338],[@B31-jcm-07-00338]\]. Therefore, it is reasonable that the CHA~2~DS~2~-VASc score could predict the risk of both thromboembolism and major bleeding.

There is a relatively high proportion of using anti-platelet agents in our study groups. It is reasonable to see the high proportion of the combination therapy to prevent bleeding among patients with acute coronary syndrome and coronary artery stenting. On the other hand, the prevalence of ischemic heart disease is not compatible with the proportion of anti-platelet, we guess that such prescription was not prolonged. Because the rate of major bleeding in this study is similar to the previous report in the United States, the predictability of the CHA~2~DS~2~-VASc score on bleeding is not affected \[[@B32-jcm-07-00338]\]. Nevertheless, the effect of combination of anti-platelets and oral anticoagulants on bleeding deserves further researches.

Our results showed that the patients in the Warfarin group had the highest prevalence rates of systemic thromboembolism and major bleeding, especially with a CHA~2~DS~2~-VASc score of four or more. Similar results have also been reported in other studies, especially in Asian populations. Possible explanations include labile international normalized ratio and specific genetic polymorphisms \[[@B33-jcm-07-00338],[@B34-jcm-07-00338],[@B35-jcm-07-00338]\]. These results highlight again that warfarin is not the best choice to treat Asian AF patients.

5. Limitations {#sec5-jcm-07-00338}
==============

There are a several limitations to this study. First, we did not compare CHA~2~DS~2~-VASc scores with other risk scores for their ability to predict major bleeding. Several scoring systems are available to estimate the risk of bleeding, such as the HAS-BLED, ORBIT, or ABC scores. Though the components of the CHA~2~DS~2~-VASc score have been well-documented in the NHIRD, some of the factors in other scoring systems could not be accurately extracted from the database. As in some other studies using national health insurance data, Taiwan's NHIRD does not include echocardiographic parameters such as ejection fraction of left ventricle, left atrial size, or right ventricular systolic function. Second, the weighting of individual risk categories in the CHA~2~DS~2~-VASc score was not well defined. Hence, we did not know which risk factors were more associated with thromboembolism or major bleeding. Third, the sample size apixaban group was relatively small because apixaban has been approved for a shorter period of time. Edoxaban, another NOAC, was not included in this study for the same reason. Researchers may wish to study these two NOACs further in the future.

6. Conclusions {#sec6-jcm-07-00338}
==============

Non-valvular AF patients with high CHA~2~DS~2~-VASc scores are susceptible to both major bleeding and systemic thromboembolism. Oral anticoagulants should be prescribed carefully for patients with high CHA~2~DS~2~-VASc scores to avoid adverse bleeding events. The outcomes of the patients with lower CHA~2~DS~2~-VASc scores were similar in the warfarin and the NOAC groups, but the NOACs were potentially more effective at reducing overall events in patients with high CHA~2~DS~2~-VASc scores. The threshold of the CHA~2~DS~2~-VASc score in terms of net benefit might be higher for NVAF patients in Taiwan.
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![Study flowchart. AF = atrial fibrillation, ESRD = end-stage renal disease.](jcm-07-00338-g001){#jcm-07-00338-f001}

![The incidence of major bleeding which required hospitalization among patients with non-valvular atrial fibrillation and receiving oral anticoagulants. Major bleeding occurred more frequently in patients with higher CHA~2~DS~2~-VASc scores.](jcm-07-00338-g002){#jcm-07-00338-f002}

![The incidence of ischemic stroke or systemic emboli requiring hospitalization among patients with non-valvular atrial fibrillation receiving oral anticoagulants. Ischemic stroke and systemic emboli occurred more frequently in the patients with higher CHA~2~DS~2~-VASc scores.](jcm-07-00338-g003){#jcm-07-00338-f003}

![Incidence of major bleeding and ischemic stroke/systemic emboli requiring hospitalization among patients with non-valvular atrial fibrillation receiving oral anticoagulants. Upper left: the apixaban group. Upper right: the rivaroxaban group. Lower left: the dabigatran group. Lower right: the warfarin group.](jcm-07-00338-g004){#jcm-07-00338-f004}

jcm-07-00338-t001_Table 1

###### 

Demographic, comorbidities, and medication used among four study groups.

                           Apixaban (*n* = 5843)   Rivaroxaban (*n* = 27,777)   Dabagatran (*n* = 20,079)   Warfarin (*n* = 19,375)   *p*-Value
  ------------------------ ----------------------- ---------------------------- --------------------------- ------------------------- -----------
  Demographics                                                                                                                        
  Age (year)               76 ± 10                 75 ± 10                      75 ± 10                     71 ± 13                   \<0.0001
  Male gender              3214 (55.01%)           15,374 (55.35%)              12,061 (60.07%)             11,221 (57.91%)           \<0.0001
  CHA~2~DS~2~-VASc score   3.89 ± 1.56             3.83 ± 1.57                  3.74 ± 1.52                 3.26 ± 1.81               \<0.0001
  Comorbidities                                                                                                                       
  Hypertension             5055 (86.51%)           23,766 (85.56%)              16,863 (83.98%)             15,099 (77.93%)           \<0.0001
  Diabetes mellitus        2389 (40.89%)           10,752 (38.71%)              7647 (38.08%)               6948 (35.86%)             \<0.0001
  PAOD                     4 (0.07%)               19 (0.07%)                   11 (0.05%)                  16 (0.08%)                0.7736
  Ischemic heart disease   733 (12.54%)            3399 (12.24%)                1961 (9.77%)                2098 (10.83%)             \<0.0001
  PCI                      415 (7.1%)              1750 (6.3%)                  916 (4.56%)                 1051 (5.42%)              \<0.0001
  CABG                     31 (0.53%)              104 (0.37%)                  40 (0.2%)                   143 (0.74%)               \<0.0001
  Heart failure            735 (12.58%)            3582 (12.9%)                 2172 (10.82%)               2699 (13.93%)             \<0.0001
  Chronic kidney disease   1671 (28.6%)            6786 (24.43%)                3922 (19.53%)               4702 (24.27%)             \<0.0001
  Chronic liver disease    929 (15.9%)             4421 (15.92%)                2831 (14.1%)                3048 (15.73%)             \<0.0001
  TIA                      167 (2.86%)             667 (2.4%)                   573 (2.85%)                 344 (1.78%)               \<0.0001
  Stroke                   1173 (20.08%)           5675 (20.43%)                4778 (23.8%)                2936 (15.15%)             \<0.0001
  History of bleeding      113 (1.93%)             644 (2.32%)                  415 (2.07%)                 451 (2.33%)               0.0841
  Medication used                                                                                                                     
  NSAID                    1556 (26.63%)           6657 (23.97%)                4401 (21.92%)               4792 (24.73%)             \<0.0001
  Anti-platelets           3231 (55.3%)            15,450 (55.62%)              10,906 (54.32%)             11,907 (61.46%)           \<0.0001
  H~2~ blocker             1810 (30.98%)           8175 (29.43%)                5772 (28.75%)               6200 (32%)                \<0.0001
  PPI                      655 (11.21%)            2906 (10.46%)                1654 (8.24%)                2421 (12.5%)              \<0.0001
  Amiodarone               1649 (28.22%)           7370 (26.53%)                4498 (22.4%)                7472 (38.57%)             \<0.0001
  Beta-blocker             3451 (59.06%)           15,782 (56.82%)              10,839 (53.98%)             11,824 (61.03%)           \<0.0001
  Statin                   229 (3.92%)             3949 (14.22%)                4101 (20.42%)               3322 (17.15%)             \<0.0001

PAOD = peripheral arterial occlusive disease, PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft, TIA = transient ischemic attack, NSAID = non-steroidal anti-inflammatory drug, PPI = proton pump inhibitor.

[^1]: The two authors contributed equally to this work.
